INBRAIN Neuroelectronics, a health-tech company dedicated to developing intelligent graphene-neural platform, has announced that its Intelligent Network Modulation System has been granted Breakthrough Device Designation (BDD) from the U.S. Food & Drug Administration (FDA) as an adjunctive therapy for treating Parkinson’s disease.

The INBRAIN system uses graphene, whose electrical and mechanical properties make it ideal for neurotechnology innovation. INBRAIN’s neural platform technology enables ultra-high signal resolution and uses machine learning software that decodes therapy-specific biomarkers to deliver highly focused, adaptive neuroelectronic therapy that re-balances pathological neural networks.

A team of researchers, led by the University of Wisconsin-Milwaukee, recently developed a path to mass-manufacture high-performance graphene sensors that can detect heavy metals and bacteria in flowing tap water. This advance could bring down the cost of such sensors to just US $1 each, allowing people to test their drinking water for toxins at home.

The sensors have to be extraordinarily sensitive to catch the minute concentrations of toxins that can cause harm. For example, the U.S. Food and Drug Administration states that bottled water must have a lead concentration of no more than 5 parts per billion. Today, detecting parts-per-billion or even parts-per-trillion concentrations of heavy metals, bacteria, and other toxins is only possible by analyzing water samples in the laboratory, says Junhong Chen, a professor of molecular engineering at the University of Chicago and the lead water strategist at Argonne National Laboratory. But his group has developed a sensor with a graphene field-effect transistor (FET) that can detect toxins at those low levels within seconds.

The MINIGRAPH project (Minimally Invasive Neuromodulation Implant and implantation procedure based on ground-breaking GRAPHene technology for treating brain disorders) aims to pave the way for a new generation of adaptive neuroelectronic therapies, resolving the most important limitations of current technology. The project revolves around the development of a new generation of graphene-based brain implants.

The project started in October 2022 and will go on for 36 months. It is a HORIZON-EIC project, with an estimated cost of €3,928,402.50. Among its members are ICN2, IMEC, Fraunhofer, INBRAIN Neuroelectronics, MSRL and more. Recently, Scientists from the Czech Advanced Technologies and Research Institute – CATRIN at Palacký University also announced that they will participate in the project.

Researchers from Seoul National University and Samsung Electronics have developed a sensitive and selective nerve gas sensor using human scent receptors. It reliably detected a substitute for deadly sarin gas in simulated tests.

Nerve gases are often very potent, requiring highly sensitive sensors to detect them quickly and accurately. One method of boosting sensitivity combines human scent receptors with nanomaterials such as reduced graphene oxide to create a "bioelectronic nose." But since these nerve gases are still highly dangerous even in laboratory settings, many scientists rely on safer, substitute molecules instead. In the case of the sarin or soman nerve agents, dimethyl methylphosphonate (DMMP) is a common replacement. Previously, the receptor protein hOR2T7 has been used to detect DMMP, but it could only do so when the nerve agent substitute was in a liquid form, rather than as a gas. So, the research team wanted to design a "nose" of their own that was both highly sensitive and selective for the gaseous form, using nanodiscs containing the hOR2T7 receptor.

Scientists at DARPA, Siemens, US ARMY, Georgia Tech Research Institute, and Paragraf - through recently acquired Cardea Bio, now Paragraf San Diego - presented novel multiomics capabilities, by detection of both protein and RNA biosignals simultaneously on a single graphene-based biosensor.

Dr. Kiana Aran, Chief Innovation Officer at Paragraf San Diego, stated: “Having a single technology platform that can detect both protein and DNA/RNA biosignal analytes at the same time on a small-scale detection device, is a major technological advancement. While it initially will impact when and where we can detect viral infections, with time it will also work for other types of diseases. This will enable new, better, and way faster diagnoses for any types of diseases or biothreats.”

Researchers from Shanghai Jiao Tong University, Chinese Academy of Fishery Sciences,  BOKU-University of Natural Resources and Life Sciences, University of Oslo and Oslo University Hospital, MIT, 2bind and Avalon GloboCare have designed a novel sensor that could detect the same molecules that naturally occurring cell receptors can identify.

The researchers created a prototype sensor that can detect an immune molecule called CXCL12, down to tens or hundreds of parts per billion. This is an important first step towards developing a system that could be used to perform routine screens for hard-to-diagnose cancers or metastatic tumors, or as a highly biomimetic electronic “nose,” the researchers say.

Researchers find a way to make the detection of antibiotic residues in water more quick and simple. The research team included scientists from the Czech Advanced Technology and Research Institute (CATRIN) at Palacký University and the Technical University of Ostrava. The new biosensor looks like a small box connected to a mobile phone. This device can immediately detect even very small antibiotic residues, namely ampicillin, in water or dairy products.

It is based on a tailor-made nanomaterial derived from fluorographene, developed by scientists from the Graphene Flagship Associated Member Czech Advanced Technology and Research Institute (CATRIN) of Palacký University and its Faculty of Science (Czech Republic). They used the so-called click chemistry method, which was awarded the Nobel Prize in Chemistry last year.

Researchers at Queen Mary University, University of Sussex and University of Brighton have integrated graphene into seaweed to create nanocomposite microcapsules for highly tunable and sustainable epidermal electronics. When assembled into networks, the tiny capsules can record muscular, breathing, pulse, and blood pressure measurements in real-time with ultrahigh precision.

The team explained that much of the current research on nanocomposite-based sensors is related to non-sustainable materials. This means that these devices contribute to plastic waste when they are no longer in use. The new study shows that it is possible to combine molecular gastronomy concepts with biodegradable materials to create such devices that are not only environmentally friendly, but also have the potential to outperform the non-sustainable ones.

Researchers from California Institute of Technology (Caltech), The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, University of California Los Angeles and Cedars-Sinai Medical Center have designed a wearable and wireless patch for the real-time electrochemical detection of the inflammatory biomarker C-reactive (CRP) protein in sweat. CRP is secreted by the liver and is commonly associated with inflammation. Its presence in the bloodstream strongly indicates an underlying health condition. CRP is much more difficult to detect because it is at a much lower concentration than other biomarkers.

The device integrates iontophoretic sweat extraction, microfluidic channels for sweat sampling and for reagent routing and replacement, and a graphene-based sensor array for quantifying CRP (via an electrode functionalized with anti-CRP capture antibodies-conjugated gold nanoparticles), ionic strength, pH and temperature for the real-time calibration of the CRP sensor.

DARPA, Siemens, the U.S ARMY, Georgia Tech Research Institute and Paragraf - through recently acquired Cardea Bio, now Paragraf San Diego - have presented novel multiomics capabilities, by detection of both protein and RNA biosignals simultaneously on a single graphene-based biosensor.

It was stated that this achievement marks the first public demonstration of this novel methodology for multiomics and that the paper is the first in the world demonstrating the capability to detect both protein and RNA biosignals in a COVID-19 based experiment where both the COVID wild type as well as the Omicron variant were successfully detected.